Alkermes Controlled Therapeutics, II
Records under this name other than patents Alkermes Controlled Therapeutics, II holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Alkermes Controlled Therapeutics, II
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,919,499 | Naltrexone Long Acting Formulations and Methods of Use Formerly held In force · High confidence | In force | High confidence | |
| US 7,279,579 | Polymorphic Forms of Naltrexone Formerly held Term ended Term ended May 7, 2026 · High confidence | Term ended | Term ended May 7, 2026 | High confidence |
| US 8,389,540 | Polymorphic Forms of Naltrexone Formerly held Lapsed on the fee record Ended Mar 5, 2025 · High confidence | Lapsed on the fee record | Ended Mar 5, 2025 | High confidence |
| US 6,987,111 | Aripiprazole, Olanzapine and Haloperidol Pamoate Salts Formerly held Term ended Term ended May 10, 2024 · High confidence | Term ended | Term ended May 10, 2024 | High confidence |
| US 8,759,351 | Methods for Administering Aripiprazole Formerly held Term ended Ended no later than Aug 6, 2023 · Low confidence | Term ended | Ended no later than Aug 6, 2023 | Low confidence |
| US 6,331,317 | Apparatus and method for preparing microparticles Term ended Term ended Nov 12, 2019 · USPTO record | Term ended | Term ended Nov 12, 2019 | USPTO record |